Evidence map›Paper›PMID 34176413›Full record

ArticleLeukemia & lymphoma2021

Impact of initial biopsy type on the time to final diagnostic biopsy in patients with follicular lymphoma and suspected histologic transformation.

Eric Mou, Lorenzo Falchi, Vandana Sundaram, Jeremy S Abramson, Ronald Balassanian, Sara Beygi, Megan J Fitzpatrick, Annabel Kate Frank, Srishti Gupta, Oscar Lin and 15 more

Erratum issuedAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia & lymphoma, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors.

Eric MouDepartment of Internal Medicine, Division of Hematology, Oncology, and Blood & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.ORCID 0000-0002-9865-4517
Lorenzo FalchiDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1531-3838
Vandana SundaramQuantitative Science Unit, Stanford University School of Medicine, Palo Alto, CA, USA.
Jeremy S AbramsonMassachusetts General Hospital, Yawkey Center, Boston, MA, USA.ORCID 0000-0001-8467-9257
Ronald BalassanianDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5756-9052
Sara BeygiDepartment of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0002-2221-4320
Megan J FitzpatrickDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0001-9336-1865
Annabel Kate FrankDepartment of Medicine, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0498-5818
Srishti GuptaDepartment of Pathology, University of Virginia, Charlottesville, VA, USA.ORCID 0000-0002-6808-7005
Oscar LinDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Joshua R ReedDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Steven R LongDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Amy LyDepartment of Pathology, Massachusetts General Hospital, Boston, MA, USA.
Joshua R MenkeDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-4499-1104
Daniel R ReedSection of Hematology and Oncology, Wake Forest Baptist Medical Comprehensive Cancer Center.ORCID 0000-0003-2965-4342
Roberto Ruiz-CorderoDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0002-9747-6069
Ashley K VolaricDepartment of Pathology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9585-812X
Yi XieDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Linlin WangDepartment of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA.
Kwun Wah WenDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Sara L ZadehDepartment of Pathology, University of Virginia, Charlottesville, VA, USA.
Yasodha NatkunamDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9816-1018
Matthew C CheungDivision of Hematology, Sunnybrook Odette Cancer Centre, Toronto, Canada.
Dita GratzingerDepartment of Pathology, Stanford University, Stanford, CA, USA.ORCID 0000-0002-9182-8123
Cyto-Heme Institutional Collaborative (CHIC) consortium

Funding

Translational Oncology Research Program (Project-005)P30CA124435 · NCI · STANFORD UNIVERSITY · PI LAURA D ATTARDI · 2007 to 2026
$71.4M
NCI NIH HHS P30 CA124435
6 · The paper itself

Abstract

Diagnosis of histologic transformation (HT) of follicular lymphoma (FL) requires tissue biopsy. While surgical biopsy represents the gold standard, less invasive procedures such as fine-needle aspiration biopsy (FNAB) and core needle biopsy (CNB) are frequently performed. In this retrospective multi-institutional study including 269 patients with FL and suspected HT, the median time from initial clinical suspicion to final diagnostic biopsy was similar whether the workup began with FNAB, CNB, or surgical biopsy (4, 9, and 6 days, respectively;

Indexed as

Lymphoma, FollicularBiopsy, Fine-NeedleBiopsy, Large-Core NeedleHumansPositron Emission Tomography Computed TomographyRetrospective Studiescore needle biopsyfine needle aspiration biopsyFollicular lymphomahistologic transformation

Identifiers

PMID34176413
PMCPMC12318888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.